Glucagon-Like Peptide 1 Receptor Agonist and Cancer. Meta-analysis and Review
ahmed z otaibi
Abstract
Abstract
Background:
Diabetes is a medical condition known and diagnosed when the human body does not use the insulin hormone effectively. This causes blood sugar levels to rise. There are 2 diabetes types. Oral hypoglycemic drugs are used in the treatment of type 2 diabetes mellitus (T2DM) while insulin used in treatment of type 1 diabetes.
Method:
Medline and Clinical Trials were searched to identify randomized controlled trials that reported cancer events in T2DM patients treated with glucagon like peptide 1 receptor agonists (GLP 1RAs). Odds ratio (OR) with 95 percent Confidence Interval (CI) was calculated for overall cancer (primary outcome), thyroid cancer and compare the results with pancreatitis.
Results:
A total of 11 eligible trials were identified. The OR for overall thyroid cancer associated with GLP 1RAs was 0.004 (95 percent CI 0.003–0.005; p
Full Text:
Background:
Diabetes is a medical condition known and diagnosed when the human body does not use the insulin hormone effectively. This causes blood sugar levels to rise. There are 2 diabetes types. Oral hypoglycemic drugs are used in the treatment of type 2 diabetes mellitus (T2DM) while insulin used in treatment of type 1 diabetes.
Method:
Medline and Clinical Trials were searched to identify randomized controlled trials that reported cancer events in T2DM patients treated with glucagon like peptide 1 receptor agonists (GLP 1RAs). Odds ratio (OR) with 95 percent Confidence Interval (CI) was calculated for overall cancer (primary outcome), thyroid cancer and compare the results with pancreatitis.
Results:
A total of 11 eligible trials were identified. The OR for overall thyroid cancer associated with GLP 1RAs was 0.004 (95 percent CI 0.003–0.005; p
PDF